A spotlight on the management of complications associated with myeloproliferative neoplasms: a clinician’s perspective

References

• Damashek DAMESHEK W. Some speculations on the myeloproliferative syndromes. Blood. 1951;6:372–375.
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organisation classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–1061.
   PubMed Web of Science ®Google Scholar
• Nangalia J, Massie CE, Baxter EJ, et al. Somatic CALR mutations in Myeloproliferative Neoplasms with non-mutated JAK2. N Eng J Med. 2013;369:2391–2405.
   PubMed Web of Science ®Google Scholar
• Pikman Y, Lee BJ, Mercher T, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS. 2006;3:e270.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Schwager S, Radia D, et al. The myelofibrosis symptom assessment form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33:1199–1203.
   PubMed Web of Science ®Google Scholar
• Scherber R, Dueck AC, Johansson P, et al. The myeloproliferative neoplasm symptom assessment form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118:401–408.
   PubMed Web of Science ®Google Scholar
• Emmanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;20:4098–4103.
   Google Scholar
• Anderson LA, James G, Duncombe AS, et al. Myeloproliferative neoplasm patient symptom burden and quality of life: evidence of significant impairment compared to controls. Am J Hematol. 2015;90:864–870.
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders(MPDs). Cancer. 2006;109:68–76.
   Web of Science ®Google Scholar
• Huberty J, Eckert R, Gowin K, et al. Feasibitlity of online yoga for symptom management in patients with myeloproliferative neoplasms. Haematologica. 2017;102:e384–8.
   PubMed Web of Science ®Google Scholar
• Gilbert HS, Warner RR, Wasserman LR. A study of histamine in myeloproliferative disease. Blood. 1966;28:795–806.
   PubMed Web of Science ®Google Scholar
• Pieri L, Bogani C, Gugliemelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia. Haematologica. 2009;94:1537–1545.
   PubMed Web of Science ®Google Scholar
• Weick JK, Donovan PB, Najean Y, et al. The use of cimetidine for the treatment of pruritus in polycythemia vera. Arch Intern Med. 1982;142:241–242.
   PubMed Web of Science ®Google Scholar
• Diehn F, Tefferi A. Pruritus in polycythaemia vera: prevalence, laboratory correlated and management. Br J Haematol. 2001;115:619–621.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonesca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood. 2002;99:2627.
   PubMed Web of Science ®Google Scholar
• Jeanmougin M, Rain JD, Najean Y. Efficacy of photochemotherapy on severe pruritus in polycythemia vera. Ann Hematol. 1996;73:91–93.
   PubMed Web of Science ®Google Scholar
• Hernandez-Nunez A, Dauden E, Cordoba S, et al. Water-induced pruritus in haematologically controlled polycythaemia vera: response to phototherapy. J Dermatol Treat. 2001;12:107–109.
   PubMed Web of Science ®Google Scholar
• Menage HD, Norris PG, Hawk JL, et al. The efficacy of psoralen photochemotherapy in the treatment of aquagenic pruritus. Br J Dermatol. 1993;129:163–165.
   PubMed Web of Science ®Google Scholar
• Baldo A, Sammarco E, Monfrecola M. UVB phototherapy for pruritus in polycythaemia vera. Dermatol Treat. 1996;7:245–246.
   Web of Science ®Google Scholar
• Baldo A, Sammarco E, Plaitano R, et al. Narrowband (TL-01) ultraviolet B phototherapy for pruritus in polycythaemia vera. Br J Bermatol. 2002;147:979–981.
   PubMed Web of Science ®Google Scholar
• Finelli C, Gugliotta L, Gamberi B, et al. Relief of intractable pruritus in polycythemia vera with recombinant interferon alfa. Am J Hematol. 1993;43:316–318.
   PubMed Web of Science ®Google Scholar
• Muller EW, De Wolf JT, Egger R, et al. Long-term treatment with interferon-alpha 2b for severe pruritus in patients with polycythaemia vera. Br J Haematol. 1995;89:313–318.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Mesa RA, Gotlib J, et al. A double -blind, placebo -controlled trial of ruxolitinib for myelofibrosis. N Eng J Med. 2012;366:799–807.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Kiladjian -J-J, Greisshammer M, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Eng J Med. 2015;372:42635.
   Google Scholar
• Geyer H, Mesa RA. Assessing disease burden in patients with classis MPNs. Best Pract Res Clin Haematol. 2014;27:107–119.
   PubMed Web of Science ®Google Scholar
• Barosi G, Ambrosetti A, Centra A, et al. Splenectomy and risk of blast transformation in myelofibrosis with myeloid transformation. Blood. 1998;91:3630–3636.
   PubMed Web of Science ®Google Scholar
• Aruch D, Schwartz M, Mascarenhas J, et al. Continued role of splenectomy in the management of myelofibrosis. Clin Lymphoma Myeloma Leuk. 2016;16:e133–7.
   PubMedGoogle Scholar
• Kitanaka A. Takenaka K Shide K et al. Splenic irradiation provides transient palliation for symptomatic splenomegaly associated with primary myelofibrosis: a report on 14 patients. Int J Hematol. 2016;103:423–428.
   PubMed Web of Science ®Google Scholar
• Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med. 1995;123:656–664.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Barbui T, et al. Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 2007;109:2446–2452.
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Rumi E, et al. In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. Blood. 2014;124:3021–3023.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization–essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–5133.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544–1551.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol. 2015;90:162–173.
   PubMed Web of Science ®Google Scholar
• Falchi L, Kantarjiaz HM, Verstovsek S. Assessing the thrombotic risk of patients with essential thrombocythemia in the genomic era. Leukemia. 2017;31:1845–1854.
   PubMed Web of Science ®Google Scholar
• Barbui T, Falanga AM. Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thromb Res. 2016;140:S71–5.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Carobbio A. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis. Blood. 2012;120:569–571.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms; ESMO Clinical Practice Guidelines. Ann Oncol. 2015;26(suppl 5):v85–v99.
   PubMedGoogle Scholar
• Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352–375.
   PubMed Web of Science ®Google Scholar
• Smalberg JH, Arends LR, Valla DC. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–4928.
   PubMed Web of Science ®Google Scholar
• Plompen EP, Valk PJ, Chu I. Somatic calreticulin mutations in patients with budd-chiari syndrome and portal vein thrombosis. Haematologica June. 2015;100:e226–8.
   PubMed Web of Science ®Google Scholar
• Tait C, Baglin T, Watson H, et al. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol. 2012;159:28–38.
   PubMed Web of Science ®Google Scholar
• Colaizzo D, Amitrano L, Guardascione MA. Outcome of patients with splanchnic venous thrombosis presenting without overt MPN: a role for the JAK2 V617F mutation re-evaluation. Thromb Res. 2013;132:e99–104.
   PubMed Web of Science ®Google Scholar
• Thatipelli MR, McBane RD, Hodge DO, et al. Survival and recurrence in patients with splanchnic vein thromboses. Clin Gastroenterol Hepatol. 2010;8:200–205.
   PubMed Web of Science ®Google Scholar
• Smalberg JH, Koehler E, Darwish Murad S, et al. The JAK2 46/1 haplotype in Budd-Chiari syndrome and portal vein thrombosis. Blood. 2011;117:3968–3973.
   PubMed Web of Science ®Google Scholar
• Barbui T, Masciulli A, Marfisi MR, et al. White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study. Blood. 2015;126:560–561.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood. 2007;109:2310–2313.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–166.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research And Treatment. Blood. 2012;120:1197–1201.
   PubMed Web of Science ®Google Scholar
• De Grandis M, Cambot M, Wautier M, et al. JAK2V617F activates Lu/BCAM-mediated red cell adhesion in polycythemia vera through an EpoR-independent Rap1/Akt pathway. Blood. 2013;121:658–665.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–124.
   PubMed Web of Science ®Google Scholar
• Zahavi J, Zahavi M, Firsteter E, et al. An abnormal pattern of multiple platelet function abnormalities and increased thromboxane generation in patients with primary thrombocytosis and thrombotic complications. Eur J Haematol. 1991;47:326–332.
   PubMed Web of Science ®Google Scholar
• Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica. 2006;91:169–175.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Vignoli A, et al. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol. 2005;33:523–530.
   PubMed Web of Science ®Google Scholar
• Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun 2017;85:58–63. pii: S0896-8411(17)30430-4.
   PubMedGoogle Scholar
• Ridker PM, Everett T, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–1131.
   PubMed Web of Science ®Google Scholar
• Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica. 2011;96:315–318.
   PubMed Web of Science ®Google Scholar
• Barbui T, Masciulli A, Ghirardi A. ACE inhibitors and cytoreductive therapy in polycythemia vera. Blood. 2017;129:1226–1227.
   PubMed Web of Science ®Google Scholar
• Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017;377:111–121.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Bareford D, Campbell P, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol. 2005;130:174–195.
   PubMed Web of Science ®Google Scholar
• Chu D, Hillis CM, Leong DP, et al. Benefits and risks of antithrombotic therapy in essential thrombocythemia. Ann Intern Med. 2017;167:170–180.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Cervantes F, Pereira A, et al. Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia. Blood. 2010;116:1205–1210.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Specchia G, et al. The CYTO-PV: a large-scale trial testing the intensity of cytoreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011:794240.
   PubMedGoogle Scholar
• Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from european leukemianet. J Clin Oncol. 2011;29:761–770.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Finazzi G. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: a propensity-matched study. Am J Hematol. 2017 Jul 11;92:1131–1136.
   Web of Science ®Google Scholar
• Björkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410–2415.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET study, a randomized controlled trial. Blood. 2013;121:1720–1728.
   PubMed Web of Science ®Google Scholar
• The BG. Use of anagrelide in myeloproliferative neoplasms, with focus on essential thrombocythemia. Curr Hematol Malig Rep. 2016;11:348–355.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Cassinat B, Chevret S, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–3072.
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a. Blood. 2013;122:893–901.
   PubMed Web of Science ®Google Scholar
• Boddu P, Falchi L, Hosing C, et al. The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: a case-based review. Leuk Res. 2017;58:14–22.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016;30:1701–1707.
   PubMed Web of Science ®Google Scholar
• Pieri L, Pancrazzi A, Pacilli A, et al. JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood. 2015;125:3352–3353.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Verstovsek S, Guglielmelli P, et al. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96:1113–1120.
   PubMed Web of Science ®Google Scholar
• Cruzado J, Rico J, Grinyó J. The renin angiotensin system blockade in kidney transplantation: pros and cons. Transpl Int. 2008;21:304–313.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• At C, Hamilton M, Mitchell SA, et al. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS One. 2015;10:e0144856.
   PubMed Web of Science ®Google Scholar
• Ianotto JC, Couturier MA, Galinat H. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol. 2017 Jun 16.
   PubMed Web of Science ®Google Scholar
• Ellis MH, Lavi N, Vannucchi A, et al. Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. Thromb Res. 2014;134:251–254.
   PubMed Web of Science ®Google Scholar
• Kaifie A, Kirschner M, Wolf D, et al. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol. 2016;9:18.
   PubMed Web of Science ®Google Scholar
• Budde U, Van Genderen PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425–431.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. How we treat essential thrombocythemia. Blood. 2016;128:2403–2414.
   PubMed Web of Science ®Google Scholar
• Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet. 2017;390:490–499.
   PubMed Web of Science ®Google Scholar
• Sekhar M, McVinnie K, Burroughs AK, et al. Splanchnic vein thrombosis in myeloproliferative neoplasms. Br J Haematol. 2013;162:730–747.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Rodeghiero F, Tosetto A, et al. Postsurgery outcomes in patients with polycythemia vera and essential thrombocythemia: a retrospective survey. Blood. 2008;111:666–671.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Mesa RA, Nagomey DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood. 2000;95:2226–2233.
   PubMed Web of Science ®Google Scholar
• Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22:235–245.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110:485–489.
   PubMed Web of Science ®Google Scholar
• Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175:31–36.
   PubMed Web of Science ®Google Scholar
• Martinelli P, Martinelli V, Agangi A, et al. Interferon alfa treatment for pregnant women affected by essential thrombocythemia: case reports and a review. Am J Obstet Gyn. 2004;191:2016–2020.
   PubMed Web of Science ®Google Scholar
• Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129:293–306.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Harrison CN, Niederwiesser D, et al. The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis. Exp Hematol Oncol. 2015;4:26.
   PubMed Web of Science ®Google Scholar